Cargando…
Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
BACKGROUND: Clopidogrel is a traditional P2Y12 receptor inhibitor that is widely used in clinical practice, but there are significant individual differences in its therapeutic effect. Carriers of the CYP2C19 deletion allele have a higher risk of adverse cardiovascular events than non-carriers. METHO...
Autores principales: | Qian, Wenwen, Chen, Liang, Zhang, Lizhu, Gao, Mingzhu, Wang, Chunxia, Qian, Xi, Yang, Chengjian, Lin, Yahui, Han, Zhijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344405/ https://www.ncbi.nlm.nih.gov/pubmed/35928614 http://dx.doi.org/10.21037/jtd-22-740 |
Ejemplares similares
-
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
por: Chen, Shuxia, et al.
Publicado: (2017) -
Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
por: Tekeste, Rahel, et al.
Publicado: (2022) -
Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018) -
Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021) -
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
por: Scanavini-Filho, Marco Antonio, et al.
Publicado: (2022)